Lipid-lowering therapy in venous thromboembolism: A Clinical Consensus Statement of the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Cardiovascular Pharmacotherapy, the ESC Working Group on Pulmonary Circulation & Right Ventricular Function, and the European Society of Vascular Medicine (ESVM)

Anticoagulation is the mainstay of venous thromboembolism (VTE) management; it may be appropriate to define lipid-lowering therapy (LLT) as risk modifier in primary prevention of VTE in populations at high CV risk

In patients with VTE, assessment of CV risk factors, including lipid levels, is commonly part of routine CV care in accordance with existing ESC Guidelines

Gaps in evidence; large-scale studies needed on the role of LLT in secondary prevention of recurrent VTE in high-risk populations